INTRODUCTION

In patients with ankylosing spondylitis (AS), anemia is found in 18.5–45.8% [1, 2, 3, 4, 5, 6, 7]. Most often, anemia in patients with AS is represented by anemia of chronic disease (ACD), the frequency of which according to various studies is 33.3% - 78.72%, however, iron deficiency anemia (IDA), caused by gastrointestinal blood loss and associated with intake of drugs for the treatment of AS, takes place at 21.28% - 66.7%, and, can coexist with ACD [3, 6]. The leading causes of ACD is shortening the life of red blood cells, iron metabolism, inhibition of the synthesis of erythropoietin and productions of cytokines, which affects erythropoiesis [8].

Recent evidence suggests that hepcidin is a major mediator of anemia and plays a central role in both homeostasis and metabolism of iron and may play a key role in the pathogenesis of ACD due to its effect on iron metabolism and its close relationship with cytokines and inflammation [9]. The connection between hepcidin, IL-6 and iron metabolism was first demonstrated by S. Pigeon et al. [10]. He showed that it stimulates IL-6 expression of acute phase protein hepcidin by hepatocytes, which in its turn inhibits iron absorption in the duodenum. Inflammation triggers the increase of hepcidin level that reduces iron absorption in the intestine and the release of iron from macrophages by biochernic mechanism known as hepcidin-ferroportin interaction [11]. That is, the total content of iron in the body is normal, but it is not enough for effective erythropoiesis [12].

In case of pure iron deficiency anemia (IDA), hepcidin concentration in serum and urine is significantly reduced. Even in the absence of anemia, hepcidin is a sensitive indicator of iron deficiency. Moreover, compared to hematocrit and hemoglobin, hepcidin reduction is an early marker of iron deficiency, along with transferrin saturation and ferritin decrease [13]. Patients with inflammatory disorders and concomitant iron deficiency typically have lower levels of hepcidin than those who are “pure” ACD [14].

So hepcidin is a promising tool that should be added to the current list of diagnostic tests status of iron, particularly in IDA because it has the potential for differential diagnosis of ACD and IDA and inform the patient’s ability to respond to therapy with oral iron [8]. In addition, there practically no data on age and sex characteristics of hepcidin concentration in blood serum, as well as its association with other factors that complicate the course of the disease.

THE AIM

The aim of the study is to evaluate the level of hepcidin in patients with AS, to determine its correlation with the disease and various forms of anemia.

MATERIALS AND METHODS

The study involved 118 patients with AS. The diagnosis of AS was made in accordance with modified New York criteria.
Among the patients studied were 102 (86.4%) males and 16 (13.6%) females. The average age of the examined patients was within 43.67 ± 0.97 years. Anemic syndrome was diagnosed in 34 (28.8%) patients as recommended by the world health organization (WHO) [16]. In 84 (71.2%) surveyed the central form of AS was

<table>
<thead>
<tr>
<th>Groups</th>
<th>Median</th>
<th>P_5</th>
<th>P_10</th>
<th>P_25</th>
<th>P_75</th>
<th>P_90</th>
<th>P_95</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control, n = 26</td>
<td>30.0</td>
<td>17.97</td>
<td>23.95</td>
<td>25.25</td>
<td>35</td>
<td>38.1</td>
<td>38.8</td>
</tr>
<tr>
<td>Patients with AS, n = 76</td>
<td>37.2</td>
<td>14.62</td>
<td>18.75</td>
<td>27</td>
<td>49.15</td>
<td>74.14</td>
<td>87.38</td>
</tr>
</tbody>
</table>

**Table I.** Percentile analysis of serum hepcidin content in almost healthy persons and patients with AS

<table>
<thead>
<tr>
<th>Groups</th>
<th>Median</th>
<th>P_5</th>
<th>P_10</th>
<th>P_25</th>
<th>P_75</th>
<th>P_90</th>
<th>P_95</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control, n = 26</td>
<td>30.10±1.36</td>
<td>8(30.8%)</td>
<td>18(69.2%)</td>
<td>0(0.0%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Patients with AS, n = 76</td>
<td>42.07±2.51</td>
<td>19(25%)</td>
<td>38(50%)</td>
<td>19(25%)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Including:

<table>
<thead>
<tr>
<th>Groups</th>
<th>Median</th>
<th>P_5</th>
<th>P_10</th>
<th>P_25</th>
<th>P_75</th>
<th>P_90</th>
<th>P_95</th>
</tr>
</thead>
<tbody>
<tr>
<td>Females on AS, n = 13</td>
<td>51.31±7.26</td>
<td>3(23.1%)</td>
<td>4(30.8%)</td>
<td>6(46.1%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Males on AS, n = 63</td>
<td>40.16±2.60</td>
<td>16(25.4%)</td>
<td>34(54%)</td>
<td>13(20.6%)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Communication with age

<table>
<thead>
<tr>
<th>Groups</th>
<th>Median</th>
<th>P_5</th>
<th>P_10</th>
<th>P_25</th>
<th>P_75</th>
<th>P_90</th>
<th>P_95</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ages 19-35, n = 18</td>
<td>39.06±4.69</td>
<td>5(27.8%)</td>
<td>9(50%)</td>
<td>4(22.2%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ages 35-55, n = 48</td>
<td>43.85±3.27</td>
<td>12(25%)</td>
<td>22(45.8%)</td>
<td>14(29.2%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ages 55-75, n = 10</td>
<td>38.92±7.20</td>
<td>2(20%)</td>
<td>7(70%)</td>
<td>1(10%)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Connection with the duration of the disease

<table>
<thead>
<tr>
<th>Groups</th>
<th>Median</th>
<th>P_5</th>
<th>P_10</th>
<th>P_25</th>
<th>P_75</th>
<th>P_90</th>
<th>P_95</th>
</tr>
</thead>
<tbody>
<tr>
<td>Up to 5 years, n = 33</td>
<td>42.25±3.88</td>
<td>10(30.3%)</td>
<td>13(39.4%)</td>
<td>10(30.3%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5-10 years, n = 30</td>
<td>44.61±4.11</td>
<td>5(16.7%)</td>
<td>16(53.3%)</td>
<td>9(30%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&gt; 10 years, n = 13</td>
<td>35.74±5.53</td>
<td>4(30.8%)</td>
<td>8(61.5%)</td>
<td>1(7.7%)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Notes: * - significance of differences with the control group, p<0.05; hepcidin level study was conducted in 76 (64.4%) patients.

**Table II.** Ranging of hepcidin levels in patients with AS and its relationship with age, sex and disease duration

<table>
<thead>
<tr>
<th>Groups</th>
<th>Median</th>
<th>P_5</th>
<th>P_10</th>
<th>P_25</th>
<th>P_75</th>
<th>P_90</th>
<th>P_95</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control, n = 26</td>
<td>30.10±1.36</td>
<td>8(30.8%)</td>
<td>18(69.2%)</td>
<td>0(0.0%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Patients with AS, n = 76</td>
<td>42.07±2.51</td>
<td>19(25%)</td>
<td>38(50%)</td>
<td>19(25%)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Including:

<table>
<thead>
<tr>
<th>Groups</th>
<th>Median</th>
<th>P_5</th>
<th>P_10</th>
<th>P_25</th>
<th>P_75</th>
<th>P_90</th>
<th>P_95</th>
</tr>
</thead>
<tbody>
<tr>
<td>Females on AS, n = 13</td>
<td>51.31±7.26</td>
<td>3(23.1%)</td>
<td>4(30.8%)</td>
<td>6(46.1%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Males on AS, n = 63</td>
<td>40.16±2.60</td>
<td>16(25.4%)</td>
<td>34(54%)</td>
<td>13(20.6%)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Table III.** The content of markers of inflammation in the serum of patients with AS (n = 76) depending on the level of hepcidin

<table>
<thead>
<tr>
<th>Characterization of groups by hepcidin level</th>
<th>Optimal (hepcidin &lt;27 ng / ml, n = 19)</th>
<th>Extremely high (hepcidin 27-49 ng / ml, n = 38)</th>
<th>High (hepcidin &gt;49 ng / ml, n = 19)</th>
</tr>
</thead>
<tbody>
<tr>
<td>CRP, ng</td>
<td>M±m</td>
<td>9.33±0.87</td>
<td>14.15±1.47*</td>
</tr>
<tr>
<td>The proportion of patients with CRP&gt;18 ng/l, n (%)</td>
<td>1(5.3%)</td>
<td>11(28.9%)*</td>
<td>7(36.8%)*</td>
</tr>
<tr>
<td>Correlation coefficient</td>
<td>r=0.30; p&lt;0.01</td>
<td></td>
<td></td>
</tr>
<tr>
<td>IL-6, g / ml</td>
<td>M±m</td>
<td>22.26±3.02</td>
<td>24.75±1.85</td>
</tr>
<tr>
<td>The proportion of patients with IL-6&gt;32.45 g/ml, n (%)</td>
<td>0(0.0%)</td>
<td>3(7.9%)*</td>
<td>7(36.8%)*</td>
</tr>
<tr>
<td>Correlation coefficient</td>
<td>r=0.36; p&lt;0.01</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ESR, mm / h</td>
<td>M±m</td>
<td>21.61±1.73</td>
<td>25.42±2.04</td>
</tr>
<tr>
<td>The proportion of patients with ESR&gt;45 mm/h, n (%)</td>
<td>0(0.0%)</td>
<td>3(7.9%)*</td>
<td>3(15.8%)*</td>
</tr>
<tr>
<td>Correlation coefficient</td>
<td>r=0.38; p&lt;0.01</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
registered, in 34 (28.8%) it was peripheral. All patients were divided into three main groups: a group of patients with AS without anemic syndrome, consisting of 84 patients, a group of patients with AS with anemic syndrome (34 patients), and a control group (26 persons), which included practically healthy people without systemic inflammatory diseases and anemia, representative of age and gender. The average age of the patients examined was within 43.67 ± 0.97 years and did not differ significantly between the patient groups.

Each patient was tested for hemoglobin (HB), erythrocytes, MCV, serum iron, total iron binding capacity (TIBC), serum ferritin, transferrin saturation (TS), and soluble transferrin receptors (sTfR). All laboratory parameters were determined by conventional methods. Hematologic parameters were determined on the ERMA PCE-210 device (Japan), biochemical parameters were determined on the hardware (Humalyzer 2000 biochemical analyzer) and the enzyme immunoassay using Stat Fax 303 / Plus using standard reagents. The content of Heps25 in serum was determined by enzyme immunoassay according to the "Human Hepsidin25 ELISA Kit" (Elabscience, USA) kit according to the instructions of the manufacturer. To evaluate the activity of the inflammatory process of AS in the serum, he content of C-reactive protein (CRP) and IL-6 enzyme immunoassay were quantified.

To determine disease activity, ASDAS (Ankylosing Spondylitis Disease Activity Score) [18] and BASDAI...
When conducting a percentile comparison (Tabl. I) it was found that the level of hepcidin was in the range of 17.9 7 – 38.8 ng/ml (P_{25} – P_{75}) in 95% of the control group, and in patients with AS in 95% was in the range of 14.62 – 87.38 ng/ml. Inasmuch as there are no clear criteria for grading hepcidin levels in the literature, we have chosen indicators that approach the P_{25} and P_{75} groups of AS patients for further analysis. We considered the optimal level of hepcidin up to 27 ng/ml (< P_{25}), extremely high - 27 – 49 ng/ml (P_{25} – P_{75}), high - above 49 ng/ml (P_{75}).

In assessing the results of analysis percentiles hepcidin content in the serum of healthy individuals and patients with AS revealed that the hepcidin P_{25} level in AS patients was 2.3 times higher than the P_{25} control group.

When comparing the average level of hepcidin in patients with AS (42.07 ± 2.51 ng/ml) and people in the control group (30.10 ± 1.36 ng/ml), it was found that in the main group, its average levels are higher by 28.5% (Tabl. II). In the AS group, 50% showed extremely high levels of hepcidin and 25% had normal and high levels of hepcidin. In the group of healthy subjects, there were no high levels of hepcidin, 69.2% had high levels and 25% had normal and high levels of hepcidin. In patients with AS, 50% showed extremely high levels of hepcidin, 44.8% had high levels and 12.8% were optimal.

Analysis of gender peculiarities in hepcidin levels showed that the latter was 21.7% higher in women than in men. No significant difference was established in the mean value of hepcidin, 69.2% had high levels and 30.8 were optimal. Analysis of gender peculiarities in hepcidin levels showed that the latter was 21.7% higher in women than in men. No significant difference was established in the mean value of hepcidin, 69.2% had high levels and 30.8 were optimal.

Analysis of gender peculiarities in hepcidin levels showed that the latter was 21.7% higher in women than in men. No significant difference was established in the mean value of hepcidin, 69.2% had high levels and 30.8 were optimal. Analysis of gender peculiarities in hepcidin levels showed that the latter was 21.7% higher in women than in men. No significant difference was established in the mean value of hepcidin, 69.2% had high levels and 30.8 were optimal.

Analysis of gender peculiarities in hepcidin levels showed that the latter was 21.7% higher in women than in men. No significant difference was established in the mean value of hepcidin, 69.2% had high levels and 30.8 were optimal.

Analysis of gender peculiarities in hepcidin levels showed that the latter was 21.7% higher in women than in men. No significant difference was established in the mean value of hepcidin, 69.2% had high levels and 30.8 were optimal.

Analysis of gender peculiarities in hepcidin levels showed that the latter was 21.7% higher in women than in men. No significant difference was established in the mean value of hepcidin, 69.2% had high levels and 30.8 were optimal.
and 44.61±4.11 ng/ml, which is 15.4% and 19.9% higher, respectively, than in the group over 10 years.

The study found (Tabl. III) that concurrently with the increase of hepcidin levels, the inflammation markers concentration (ESR, CRP, IL-6) increased in serum. Thus, significant differences were observed in the levels of markers of the inflammatory process between groups with extremely high and optimal levels of hepcidin. Furthermore, in the high hepcidin group, the mean values as well as the proportion of individuals with high levels of ESR, CRP and IL-6 were even more striking. In particular, in the group with high levels of hepcidin, compared to its optimal level, mean ESR, CRP and IL-6 values were 21% - 38% higher. The largest number of patients with high levels of CRP, IL-6 and ESR were detected in the group with high hepcidin. The close connection between inflammatory process markers on the one hand and hepcidin levels on the other was confirmed by correlation analysis.

In the next part of our study we evaluated the extent to which the disease activity according to BASDAI, ASDAS and VAS questionnaires changed depending on hepcidin levels (Tabl. IV). It was found that with increasing hepcidin concentration the proportion of patients with high levels of BASDAI and ASDAS increased. In particular, the proportion of individuals with high BASDAI and ASDAS values in the high hepcidin group compared to the optimal values was 1.38, and 8.3 times higher, respectively. There are no significant differences depending on VAS scale and hepcidin levels.

As hepcidin plays a key role in the metabolism of iron, we rated its level in the patient groups with and without anemia (Tabl. V).

It was found that in patients without anemia (36.08±2.57 ng/ml) the average hepcidin value significantly differed from the group of patients with anemia (51.77±4.62 ng/ml). The proportion of people with high hepcidin among people with anemia appeared to be 3.5 times higher than in patients without anemia. The lowest level of hepcidin was found in persons with signs of IDA (35.84±7.50 ng/ml), and the highest (62.78±5.94 ng/ml) in groups and patients with ACD. ACD group with functional iron deficiency took an intermediate position in terms of hepcidin levels (48.53±9.50 ng/ml).

Hepcidin analysis depending on the degree of anemia showed that people with mild anemia degree had 23% higher hepcidin level than patients with an average degree of anemia. We believe, however, that the vast majority of patients with grade 2 anemia had the actual IDA, which was characterized by lower levels of hepcidin, and patients with grade 1 anemia had signs of ACD and ACD with functional deficiency of iron.

The same differences are observed in the comparative analysis of groups by cytometric characteristics. The highest levels of hepcidin and the highest number of persons with high levels of the latter were recorded in the groups with normocytic (52.9%) and macrocytic anemia (50%), compared to 37.5% in the group with microcytosis, since microcytic changes of erythrocytes are more characteristic of IDA, while ACD and ACD with functional deficiency of iron are characterized by normocytosis and macrocytosis.

We have also conducted an analysis of levels of hepcidin with hematopoiesis and ferrokinetics markers in AS patients with anemia and without it (Tabl. VI). In the group of patients without anemia we found no association of hepcidin with red blood and ferrokinetics.

Whereas, in persons with anemia, the association of hepcidin with serum iron, the transferrin saturation with iron and ferritin was clearly traced. Thus, in the group with the optimal level of hepcidin, the level of iron (8.76±0.39 μmol/l) was the lowest. Significantly higher levels of this indicator were in people with very high and highest hepcidin. The same tendency is characteristic of TS, the lowest of which was in the group with the optimal level of hepcidin (15.52±1.52%), intermediate (16.80±1.62%) in persons with extremely high, and highest (19.33±0.89%) in those with the high level. With regard to soluble transferrin receptors, with the growth of hepcidin their level was decreasing from 6.02±0.71 mg/l in the group with the optimum hepcidin level to 4.88±0.64 mg/l in the group with high hepcidin. Ferritin, like hepcidin, responded to inflammation by increasing its amount. It was 16.6% higher in the group with extremely high levels of hepcidin and 35% higher in the group with high levels of hepcidin compared to the group with its optimal value.

DISCUSSION

Thus, evaluation of hepcidin levels in patients with AS showed that their levels are significantly higher in patients of the main group than in healthy individuals. In the AS group, only 25% of those surveyed had normal values, 50% had extremely high and 25% had high values. In the group of healthy subjects, high levels of hepcidin were not registered, in 69.2% were extremely high levels and in 30.8% were optimal. The data obtained by us is consistent with the results of the Turkish population of AS patients [8], according to which serum levels of hepcidin in AS patients were 1.6 times higher than in control subjects (73.77 ± 15.36 mg/dl, against 45.82±10.71 mg/dl, p<0.05, respectively).

The study did not reveal any gender differences in hepcidin levels, as well as the age and duration of the disease.

One of the unfavorable pathogenetic factors of hepcidin synthesis disorders is the systemic inflammatory process. We have shown that the increase in serum levels of hepcidin in patients with AS is associated with the severity of organ lesions and the activity of the inflammatory process. Thus, in individuals with high hepcidin levels, the activity of AS on the BASDAI and ASDAS scale was between 1.38 and 8.3 times higher than its optimal levels. It has also been found that the majority of individuals with high BASDAI and ASDAS levels is accumulated in groups of patients with high hepcidin in particular. Our data demonstrates that CRP, IL-6, and ESR levels in serum show a strong direct correlation with hepcidin levels. It is in the group with their high levels that individuals with high levels of inflammatory markers are accumulated.
The data obtained by us is consistent with the results of separate studies that have demonstrated a link between the level of proinflammatory mediators and disorders of hepcidin synthesis in patients with AS [8, 20].

Levels of serum hepcidin and prohepcidin are significantly higher in patients with inflammatory bowel disease [21], in patients with active systemic lupus erythematosus [22], and rheumatoid arthritis [23, 24]. According to [4], treatment with infliximab in patients with AS led not only to a decrease in the concentration of IL-6 and TNF-α, but also to a decrease in serum hepcidin levels and to reduction of anemia symptoms.

We found that in the group of patients with anemia, hepcidin levels were 1.4 times higher than in those without anemia. This was due to the accumulation of a proportion of individuals with high levels of hepcidin among individuals with anemia. Similar results were obtained in the Russian population of patients with AS, in particular in the group with anemia there was an increased level of hepcidin in 31.91% of persons, and without anemia only in 10 (20%) of the examined [3].

In the analysis of hepcidin concentration, depending on the pathogenetic variants of anemia, we found that patients with IDA had the hepcidin level practically comparable to the group of patients without anemia and / or control group. Patients with ACD were characterized by the highest levels of hepcidin.

Literature also clearly indicates that patients with ACD have significantly higher levels of hepcidin than patients with IDA [25]. In particular, RA patients with verified IDA, despite the high activity of the inflammatory process, on the contrary, showed a significant decrease in the concentration of hepcidin in the serum, which is quite comparable in terms of the role of hepcidin in iron metabolism and the desire of the body to fill its normal body of hemoglobin synthesis. Hepcidin concentration was also found to be higher in patients with normocytic and macrocytic anemia compared with the group with microcytic anemia.

Regarding the peculiarities of hematopoiesis and ferrokinetics, the connection between hepcidin and serum iron, the transferrin saturation with iron and serum ferritin was clearly traced in anemic individuals. Similar results were obtained in recent studies in RA patients [14], which established a close positive and social association of hepcidin with ferritin (P >0.001), while hemoglobin, serum iron, and TIBC had a negative correlation with hepcidin.

In individuals with high hepcidin levels, the activity of AS on the BASDAI and ASDAS scale was between 1.38 and 8.3 times higher than its optimal levels.

3. A close pathogenetic connection of hepcidin is established with the formation of anemic syndrome. Levels of hepcidin in patients with anemia are 1.4 times higher than in individuals without anemia. In the analysis of the concentration of hepcidin, depending on the pathogenetic variants of anemia, it was found that patients with IDA had a level of hepcidin practically comparable to the group of patients without anemia and / or control group. Patients with ACD were characterized by the highest levels of hepcidin. The ACD group with iron deficiency at hepcidin levels (48.53 ± 9.50 ng / ml) occupied an intermediate position.

4. Since close associative relationships are established between hepcidin levels and inflammatory activity indicators, ferritin levels and serum iron levels, it can be considered that hepcidin plays an important role in the pathogenesis of ACD in patients with AS and can be used as a diagnostic marker for differential diagnosis of IDA and ACD.

Directions for further researches are to find effective treatments for anemic syndrome in patients with AS.

REFERENCES

CONCLUSIONS
1. High levels of hepcidin are found in 25% of patients with AS, in 50% limit and only 25% of their optimal values. There were no high levels of hepcidin among healthy subjects, 69.2% showed extremely high levels and 30.8% were optimal.
2. The levels of hepcidin in the serum of patients with AS are independent of the age, sex and duration of the disease, but are closely associated with the activity (levels of ESR, CRP, IL-6, BASDAI and ASDAS) of the disease.

Levels of serum hepcidin and prohepcidin are significantly higher in patients with inflammatory bowel disease [21], in patients with active systemic lupus erythematosus [22], and rheumatoid arthritis [23, 24]. According to [4], treatment with infliximab in patients with AS led not only to a decrease in the concentration of IL-6 and TNF-α, but also to a decrease in serum hepcidin levels and to reduction of anemia symptoms.

We found that in the group of patients with anemia, hepcidin levels were 1.4 times higher than in those without anemia. This was due to the accumulation of a proportion of individuals with high levels of hepcidin among individuals with anemia. Similar results were obtained in the Russian population of patients with AS, in particular in the group with anemia there was an increased level of hepcidin in 31.91% of persons, and without anemia only in 10 (20%) of the examined [3].

In the analysis of hepcidin concentration, depending on the pathogenetic variants of anemia, we found that patients with IDA had the hepcidin level practically comparable to the group of patients without anemia and / or control group. Patients with ACD were characterized by the highest levels of hepcidin.

We found that in the group of patients with anemia, hepcidin levels were 1.4 times higher than in those without anemia. This was due to the accumulation of a proportion of individuals with high levels of hepcidin among individuals with anemia. Similar results were obtained in the Russian population of patients with AS, in particular in the group with anemia there was an increased level of hepcidin in 31.91% of persons, and without anemia only in 10 (20%) of the examined [3].

In the analysis of hepcidin concentration, depending on the pathogenetic variants of anemia, we found that patients with IDA had the hepcidin level practically comparable to the group of patients without anemia and / or control group. Patients with ACD were characterized by the highest levels of hepcidin. The ACD group with iron deficiency at hepcidin levels (48.53 ± 9.50 ng / ml) occupied an intermediate position.

Since close associative relationships are established between hepcidin levels and inflammatory activity indicators, ferritin levels and serum iron levels, it can be considered that hepcidin plays an important role in the pathogenesis of ACD in patients with AS and can be used as a diagnostic marker for differential diagnosis of IDA and ACD.

Directions for further researches are to find effective treatments for anemic syndrome in patients with AS.

REFERENCES
19. Rheumatol J. Bath ankylosing spondylitis functional index. 1995. 34(8), 793-794

This study is a part of the research work «To study the role of clinical, molecular genetic, metabolic, immune-inflammatory and hemocoagulation factors in the formation of cardiovascular lesions in rheumatoid arthritis, and to develop recommendations for their prevention and treatment», the state registration number is 0113U000670.

ORCID and contributionship:
Sergii V. Shevchuk: 0000-0002-5649-2775
Oksana V. Zviahina: 0000-0002-1840-8288
Inna P. Kuvikova: 0000-0003-1891-6263
Iulia S. Segeda: 0000-0001-8282-7703

Conflict of interest:
The Authors declare no conflict of interest.

CORRESPONDING AUTHOR
Oksana V. Zviahina
National Pirogov Memorial Medical University
56 Pirogov st., 21018 Vinnytsia, Ukraine
tel:+380963459619
e-mail: zviahina89@gmail.com

Received: 22.11.2019
Accepted: 10.06.2020